PHMM.F Stock Overview
A biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €75.00 |
| 52 Week High | €75.00 |
| 52 Week Low | €26.85 |
| Beta | 0.044 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 12.92% |
| 5 Year Change | 2,961.22% |
| Change since IPO | 3,233.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHMM.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how PHMM.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PHMM.F performed against the US Market.
Price Volatility
| PHMM.F volatility | |
|---|---|
| PHMM.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHMM.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PHMM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 509 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer.
Pharma Mar, S.A. Fundamentals Summary
| PHMM.F fundamental statistics | |
|---|---|
| Market cap | US$1.34b |
| Earnings (TTM) | US$647.71k |
| Revenue (TTM) | US$173.91m |
2,073x
P/E Ratio7.7x
P/S RatioIs PHMM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHMM.F income statement (TTM) | |
|---|---|
| Revenue | €167.00m |
| Cost of Revenue | €9.32m |
| Gross Profit | €157.68m |
| Other Expenses | €157.06m |
| Earnings | €622.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.035 |
| Gross Margin | 94.42% |
| Net Profit Margin | 0.37% |
| Debt/Equity Ratio | 27.9% |
How did PHMM.F perform over the long term?
See historical performance and comparison